Eriksson, A
Österroos, A
Hassan, S
Gullbo, J
Rickardson, L
Jarvius, M
Nygren, P
Fryknäs, M
Höglund, M
Larsson, R
Article History
Received: 24 February 2015
Accepted: 6 March 2015
First Online: 17 April 2015
Competing interests
: RL, PN and MF are co-founders and shareholders of Repos Pharma AB, a small Swedish research and development company dedicated to investigations of drug repositioning in the cancer area. The remaining authors declare no conflict of interest.